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ABSTRACT The hypothesis for this research was that regional cerebral blood flow
(rCBF) would increase following nasal nicotine administration to overnight abstinent
tobacco smokers in relationship to the known brain distribution of nicotinic cholinergic
receptors (nAChRs). Nine male and nine female healthy adult smokers were studied.
They abstained overnight from tobacco products for 10 or more hours prior to study the
next morning. Nicotine nasal spray was given in doses of 1–2.5 mg total with half in each
nostril while the subject was awake and resting in a supine position. Oleoresin of pepper
solution in a similar volume was used as an active placebo to control for the irritating
effects of nicotine. Both substances were given single blind to the subjects. Positron
emission tomography (PET) with H2
15O was used to measure rCBF. The data from each
subject volunteer were normalized to global activity to better assess regional brain
changes. Both nasal nicotine and pepper spray produced similar increases in CBF in
somesthetic area II, consistent with the irritant effects of both substances. The mean
rCBF effects of nasal pepper were subtracted from those of nasal nicotine to determine
the actions of nicotine alone. The latter produced increases in rCBF in the thalamus,
pons, Brodman area 17 of the visual cortex, and cerebellum. Some brain areas that
contain a large number of nAChRs, such as the thalamus, showed an increase in CBF.
Other areas that have few nAChRs, such as the cerebellum, also showed an increase in
relative CBF. The hippocampal/parahippocampal areas showed greater regional de-
creases (left) and lesser increases (right) in CBF that correlated with the increase in
plasma arterial nicotine concentrations. The results obtained indicate complex primary
and secondary effects of nicotine in which only some regional brain CBF changes
correlate with the known distribution of nAChR. No gender differences were noted.
Synapse 38:313–321, 2000. © 2000 Wiley-Liss, Inc.
INTRODUCTION
Studies on the functional significance of nicotinic
cholinergic receptors (nAChRs) in the brain are an
active area of research. It is of interest not only to
scientists but also to members of society concerned
with the issues of nicotine and tobacco addiction,
health, compensation, economics, taxation, etc. Nico-
tine is the primary pharmacological agent in tobacco,
with numerous complex actions (Larson et al., 1961;
Ejrup, 1965; Larson and Silvette, 1968, 1971; Dunn,
1973; Balfour, 1984; Adlkofer and Thurau, 1985; Ney
and Gale, 1989; Rand and Thurau, 1988; Clarke et al.,
1995). The seminal U.S. Surgeon General’s Report in
1998 stressed the addictive potential of nicotine in
tobacco.
New brain imaging techniques have made such nic-
otine and tobacco research in humans feasible (Domi-
no, 1995). One major action of nicotine demonstrated in
animals is to stimulate the brainstem activating sys-
tem resulting in short-lasting EEG activation and be-
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havioral arousal (Domino and Yamamoto, 1965;
Yamamoto and Domino, 1965). Lesions of the brain-
stem prevent nicotine-induced EEG activation, sug-
gesting important neuronal circuitry involving this
area (Kawamura and Domino, 1969). In rat brain the
autoradiographic distribution of 3H-acetylcholine (3H-
ACh) and 3H-nicotine is quite different from 125I-a-
bungarotoxin, indicating major regional brain differ-
ences in subtypes of nAChRs (Clarke et al., 1985). Both
3H-ACh and 3H-nicotine binding is highest in the in-
terpeduncular nucleus, most thalamic nuclei, superior
colliculus, medial habenula, presubiculum, layers I,
III, and IV of the cerebral cortex, substantia nigra pars
compacta, and the ventral tegmental area. The nico-
tinic cholinergic agonists, epibatidine and A-85380,
when radiolabeled bind predominantly a4b2 AChRs in
the thalamus and other brain areas in animals (Bott-
laender et al., 1997; Ding et al., 1997; Horti et al., 1997;
Chefer et al., 1998; Kimes et al., 1998; Koren et al.,
1998; Mukhin et al., 1998; Vaupel et al., 1998). It is of
interest to determine whether nicotine directly or indi-
rectly affects similar brain structures in humans. Ac-
tivation of nicotinic cholinergic receptors releases a
large number of excitatory and inhibitory neurotrans-
mitters and modulators. Therefore, both regional in-
creases and decreases in cerebral blood flow were ex-
pected following nicotine administration where nAChR
are located, as well as at more distant sites of neuronal
activation or suppression.
A readily available form of nicotine approved by the
U.S. Food and Drug Administration is a spray device
for nasal administration. This route produces blood
levels of nicotine which better mimic inhalation via
tobacco smoke than either nicotine gum or skin
patches. In the present study, nasal nicotine was com-
pared to nasal oleoresin of pepper administration in a
single-blind study of their effects on normalized rCBF




This study was approved by the Investigational Re-
view Board for Human Subject Research at the Uni-
versity of Michigan Medical Center. All candidates who
agreed to participate provided informed consent. Sub-
jects were recruited through advertisements in local
newspapers and via community bulletin boards. Can-
didates who appeared to be eligible on the basis of a
preliminary telephone screen were invited to a screen-
ing interview, at which time the study was explained. A
physical examination was performed and laboratory
tests were obtained, including a complete blood count,
electrolytes, liver function tests, urinalysis, and a urine
toxicology screen for drugs of abuse. Additionally, all
candidates underwent a psychiatric screening inter-
view using the Structured Clinical Interview DSM IV
(SCID IV). Women were given a pregnancy test prior to
inclusion in the study. Subjects who met the above
criteria completed a Fagerström test to provide a pre-
liminary assessment of the degree of nicotine depen-
dence.
Inclusion and exclusion criteria
Subjects were male or female tobacco smokers who
smoked 15–40 cigarettes per day, between 18–52 years
of age, in good physical health, and not taking any
medications (except oral contraceptives or replacement
hormones). Individuals suffering from renal, hepatic,
cardiovascular, hematological, neurological, psychiat-
ric, or endocrinological disease were excluded. Fertile
women who were not using an acceptable method of
birth control (oral contraceptives, a barrier method,
intrauterine device, or levonorgestrel implants) were
excluded. Also, those who met criteria for psychoactive
substance abuse disorder on the SCID IV were ex-
cluded, as were those who revealed evidence of recent
use of an abused substance other than nicotine in the
urine toxicological screen.
Procedure
Subjects were taught to use an FDA-approved nico-
tine nasal spray device prior to the study day. Subjects
reported to the PET suite of the Nuclear Medicine
Division of University Hospital at 8:00 AM on the day of
the study, following overnight abstinence from tobacco
products (.10 h). A sample of expired air was analyzed
for carbon monoxide (CO) in parts per million (ppm).
Expired air CO levels .10 ppm in the subject required
an extensive interview to ascertain possible noncompli-
ance with the no-smoking directive within the past
10 h. Also, ECG and systemic arterial blood pressure
were monitored throughout the study (Marquette Elec-
tronics, Milwaukee, WI; Series 7000 monitor).
Following an explanation of the imaging procedure,
the subject lay supine in the PET gantry. For each
subject, six PET scans were conducted at 12–15-min
intervals using H2
15O to determine rCBF. The experi-
mental session consisted of the following: scan #1—5%
CO2 in 95% O2; scan #2—baseline; scan #3—nasal
spray of oleoresin of pepper placebo; scan #4—recovery
from pepper placebo; scan #5—nasal spray of nicotine;
scan #6—partial recovery from nicotine. Both venous
and arterial access lines were placed in the forearms of
the subjects prior to the rCBF sessions for obtaining
blood for plasma nicotine concentrations and arterial
pCO2 and pO2 levels. The latter were performed by the
University of Michigan Clinical Arterial Blood Gas
Analysis Laboratory. About 3 min before the third and
fifth scans, either placebo or nicotine spray (0.5 mg/
spray) was administered intranasally. A total of 2–5
sprays were administered, depending on the volun-
teer’s ability to tolerate the nicotine. Arterial and ve-
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nous blood samples for nicotine and cotinine were with-
drawn before and after the fifth and sixth scans.
Samples were drawn prior to, and about 3, 6, 10, 15, 20,
and 30 min following nicotine administration. Blood
samples were collected in standard 5 ml EDTA vacu-
tainer tubes and stored immediately on crushed ice.
Immediately following completion of the study the
samples were centrifuged and plasma aliquots were
frozen at 220°C until analysis. Venous and arterial
samples were analyzed for nicotine and cotinine using
HPLC techniques (Hariharan et al., 1988). The nico-
tine and cotinine data have been reported in detail
elsewhere (Guthrie et al., 1999).
PET imaging and data analysis
PET imaging was performed using a Siemens/CTI
931/08-12 scanner that collects 15 tomographic slices
with a slice-to-slice separation of 6.75 mm (Spinks et
al., 1988). A patient’s head was positioned in the PET
gantry using a 3-min transmission scout view to cover
the region from the top of the brain to the middle of the
cerebellum. A 12-min transmission scan was then ob-
tained for the purpose of attenuation correction of the
emission scans. Head position was maintained by soft
restraints and monitored by laser beams. For each
emission scan, the subject received an i.v. injection of
50 mCi H2
15O. The H2
15O was prepared in the Univer-
sity of Michigan Nuclear Medicine Cyclotron facility.
Data acquisition began 5 sec after the arrival of radio-
activity in the brain and continued for 60 sec.
Small head motions during emission scans were cor-
rected by an automated computer algorithm for each
subject before analysis (Minoshima et al., 1993). Im-
ages were then transformed to the standard bicommis-
sural stereotactic coordinate system (Talairach and
Tournoux, 1988) using automated linear scaling and
nonlinear warping algorithms (Minoshima et al.,
1994), which permitted pixel-by-pixel analyses of cere-
bral activities across subjects in a reproducible man-
ner. Pixel counts of each image set were normalized to
whole brain activity prior to statistical analysis. Nor-
malized pixel counts were used as a marker of regional
neuronal activities (Fox and Raichle, 1984). Statistical
subtraction analyses were performed across subjects
for the following conditions. To examine changes in
cerebral activities induced by nicotine alone, the data
of scan #2 (baseline) was subtracted from the data of
scan #5 (nasal spray of nicotine). Similarly, the data of
scan #2 was also subtracted from scan #3 (nasal spray
of oleoresin of pepper placebo) to detect changes in
brain activities induced by the active placebo spray.
Nicotine spray induced an irritating sensation in the
nasal cavity that could be partially reproduced by the
application of pepper placebo spray. To detect more
specifically changes in brain activities induced by di-
rect effects of nicotine in the central nervous system,
scan #3 data (pepper placebo) was also subtracted from
scan #5 (nicotine) to remove effects of nasal sensation.
The other possible confounding factor was the direct
effect of nicotine on cerebral vasculature that may have
induced changes in cerebral blood flow independent
from neuronal activities. To partially address this is-
sue, the heterogeneity in regional vascular responsive-
ness was examined by subtracting the data of baseline
scan #2 from scan #1 obtained with a vascular dilator
(5% CO2 in 95% O2) and compared to the results of the
nicotine spray. In order to examine the lasting effects
of placebo pepper spray and nicotine spray, recovery
scans (scans #4 and #6) were obtained after scan #3
(pepper placebo) and scan #5 (nicotine spray), respec-
tively, and subtraction analyses with baseline scan #2
were performed. In addition, the correlation between
the arterial plasma nicotine concentration at the time
of the changes in rCBF was investigated by image-
based correlational analysis. Gender differences in re-
sponse to nicotine were also investigated by the sub-
traction analysis between male and female image
results.
In the statistical subtraction analyses, only gray
matter pixels (pixels with normalized activities .60%
of the global value) were included in the analyses. To
compensate for small residual anatomic variations
across subjects and to improve signal-to-noise ratios, a
three-dimensional Gaussian filter (FWHM 9 mm) was
applied to each scan. For each subtraction analysis,
one-sample t-statistic values were calculated for each
pixel using a pooled variance across pixels (Worsley et
al., 1992). The use of a pooled variance approximated a
normal Gaussian distribution on resultant statistical
maps. To detect areas of significant differences, a sta-
tistical threshold that controlled a Type-I error rate at
P 5 0.05 for multiple comparisons was estimated at
Z 5 4.00 using the Euler characteristic (Worsley et
al., 1992) based on the number of pixels in the gray
matter and image smoothness (Friston et al., 1991). In
the correlation analysis, correlation coefficients be-
tween normalized pixel values and arterial nicotine
levels were calculated on a pixel-by-pixel basis across
subjects and then transformed to Z values using a
Fisher’s transformation. A critical threshold to delin-
eate brain activities significantly correlating with
plasma nicotine was estimated at Z 5 4.2 based on
the theory described above. In the analysis examining
gender differences in brain response to nicotine, two-
sample t-statistic values were calculated between male
and female groups on a pixel-by-pixel basis and then
converted to Z values using probability integral trans-
formation (Friston et al., 1991). The critical threshold
to determine brain activities that would show signifi-
cant gender differences was estimated at Z 5 4.0.
Medications
Nasal nicotine spray was obtained by medical pre-
scription from Dr. E.B. Nelson of McNeil Consumer
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Products (Fort Washington, PA). Nasal oleoresin of
pepper spray was obtained from Dr. K.O. Fagerström,
Pharmacia and Upjohn A.B. (Helsingborg, Sweden).
RESULTS
Plasma nicotine, cardiovascular, and
subjective effects
The mean data of plasma nicotine and its cardiovascu-
lar effects (n 5 15–19) are summarized in Figure 1. As in
Figure 1a, before nasal nicotine, the mean 6 SD plasma
arterial concentration was 2.09 6 1.98 and after the peak
concentration was 16.73 6 5.62 ng/ml (P , 0.0001). The
mean 6 SD plasma venous concentration was 2.36 6 2.06
and after 8.03 6 3.82 ng/ml (P , 0.0001). The nicotine
plasma levels decreased rapidly, consistent with its
known alpha t1/2 of about 8 min (not shown). Before nasal
pepper, the mean heart rate 6 SD was 61.95 6 10.04/min
and after 65.69 6 9.06/min (P . 0.05). This slight in-
crease continued for at least 15 min. After nasal nicotine,
the mean heart rate 6 SD was 92.74 6 11.33/min (P ,
0.001). The nicotine-induced heart rate increase returned
gradually toward control levels over the next 30 min, but
was still elevated. As illustrated in Figure 1c, the mean 6
SD peak systolic arterial blood pressure before nasal pep-
per placebo was 116.22 6 10.76 mm Hg and after
120.72 6 11.57 mm Hg (P , 0.05). The mean 6 SD
systolic blood pressure after nasal nicotine spray was
132.63 6 11.94 mm Hg (P , 0.001, see Fig. 1C). The
mean 6 SD diastolic blood pressure before nasal pepper
spray was 68.21 6 7.54 mm Hg and after 72.17 6 9.52
mm Hg (P . 0.05, Fig 1D). The mean 6 SD diastolic
blood pressure after nasal nicotine spray was 80.16 6
9.49 mm Hg (P , 0.001). When the subjects were asked
which spray was more likely nicotine the answers were
random. In contrast, the investigators, even when
blinded to which spray was given, could easily tell when
nicotine was administered on the basis of its obvious
cardiovascular effects.
PET imaging results
Nicotine nasal spray increased normalized cerebral
blood flow in multiple structures of the brain (Fig. 2,
Table I). A large increase was seen in the cerebellar
hemisphere and vermis. Increased blood flow was also
noted in the pons and thalamus bilaterally in these
deep brain structures. Nicotine induced a neocortical
increase in cerebral blood flow in the premotor cortex
bilaterally, in the primary visual cortex, peaking in the
Fig. 1. Effects of nasal nicotine and pepper placebo spray on mean
plasma nicotine concentrations and various cardiovascular parame-
ters. A: Peak nicotine concentrations before and after nicotine nasal
spray. B: Mean heart rate over time following nasal nicotine and
pepper spray. C: Mean peak systolic blood pressure. D: Mean diastolic
blood pressure taken at the time of peak systolic pressure. *P ,
0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001, n 5 15 to 19
subjects when data available.
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Fig. 2. Increased regional cerebral blood flow by nicotine and
pepper placebo nasal spray. The results of the statistical subtraction
analyses (Z score) of nicotine — baseline (first row), pepper placebo —
baseline (middle row), and nicotine — pepper placebo (bottom row)
are superimposed on standard brain surface images. Right lateral
(RT.LAT), left lateral (LT.LAT), right medial (RT.MED), and left
medial (LT.MED) views of the brain are shown. Red to yellow pixels
represent increased cerebral activities associated with statistical sig-
nificance greater than P , 0.05 (not corrected for multiple compar-
isons). Significant peak changes after controlling for multiple compar-
ison are listed in Table I.
Fig. 3. Control scans obtained during the partial recovery phases
of nicotine and pepper placebo nasal sprays and during CO2 inhala-
tion. The color coding is the same as that in Figure 1. See also Table
II. The results of 12–15 min recovery from nicotine spray (bottom row)
and from pepper placebo spray (top row) are important controls. The
mean scan with CO2 inhalation indicates the abstinent tobacco smok-
ers had an increase in rCBF primarily in amygdala.
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lingual gyrus, and right inferior temporal gyrus. There
was a significant increase in blood flow within the
rectal gyrus. However, a large increase in blood flow in
the nasal cavity (presumably due to a direct mucosal
effect) partially obscured the increase in the rectal
gyrus.
The active pepper placebo spray produced an over-
lapping, but also distinct pattern of normalized in-
creased brain blood flow compared to that of nicotine
spray (Fig. 2, Table I). The overlapping areas of in-
creased flow included the cerebellar hemisphere, ver-
mis, premotor cortex, and rectal gyrus. An increase in
cerebral blood flow in the right ventral anterior cingu-
late cortex and left anterior insula was unique to the
pepper placebo. The overlapping areas of increased
blood flow presumably represent brain structures re-
sponding to nasal irritation caused by both the nicotine
and pepper sprays.
As noted in Table I, there were also statistically
significant normalized decreases in CBF in various
brain structures with both nicotine and the pepper
placebo.
The mean normalized cerebral blood flow effects of
nicotine spray minus those of the pepper spray were
performed to determine more specifically the effects of
nicotine not due to nasal irritation. This analysis was
designed to subtract out brain activation associated
with nasal irritation with nicotine. Significant in-
creases in normalized blood flow were found in the
cerebellum, thalamus, pons, right fronto-temporal
operculum, and primary visual cortex (Fig. 2, Table I).
The recovery scan #6 was obtained approximately
12–15 min after nicotine spray. It showed increased
flow in the rectal gyrus, ventral medial frontal cortex,
and cerebellum bilaterally (Fig. 3, Table II). However,
other foci of significant activation seen with the nico-
tine spray were no longer present, indicating a rela-
tively short duration of action of nicotine in those struc-
tures. In addition, pepper placebo recovery analysis
also showed a similar pattern of residual blood flow
increases in the rectal gyrus and ventral medial frontal
cortex (Fig. 3, Table II), suggesting these changes may
be associated with the application of irritable nasal
sprays instead of specific effects of nicotine.
The correlation analysis between arterial nicotine
levels and changes in normalized regional brain activ-
ities showed marginally significant “negative” correla-
tion in the left parietal operculum (Z 5 2 4.3) and in
the region of the left hippocampus/parahippocampal
gyrus (Z 5 2 4.2, Fig. 4). Interestingly, the right
TABLE I. Normalized changes in regional cerebral blood flow






Nicotine minus baseline (scan 5 minus scan 2)
Left cerebellum (28, 276, 240) 12% 6.3
(21, 280, 234) 9% 5.5
(24, 280, 227) 7% 5.2
(26, 260, 222) 6% 4.4
(42, 260, 229) 7% 4.3
(48, 251, 225) 6% 4.2
Right cerebellum (212, 278, 234) 10% 5.8
(235, 258, 227) 8% 5.7
(237, 262, 236) 9% 5.1
(221, 285, 225) 6% 4.0
Lingual gyrus (6, 291, 211) 8% 5.7
Vermis (1, 260, 222) 8% 5.6
Rectal gyrus (3, 30, 222) 11% 5.7
Pons (21, 224, 227) 8% 4.9
Right premotor (260, 3, 16) 7% 4.9
Thalamus (1, 215, 11) 6% 4.6
Left premotor (62, 21, 16) 6% 4.5
Nasal sinus (1, 5, 222) 8% 4.9
Right inferior temporal (251, 19, 216) 7% 4.3
Anterior cingulate (1, 28, 32) 26% 24.0
Left inferior temporal (33, 253, 24) 26% 24.0
(39, 269, 2) 26% 24.5
Right inferior parietal (221, 258, 50) 26% 24.2
Right inferior temporal (242, 260, 22) 26% 24.4
Right middle temporal (48, 253, 22) 27% 24.7
Pepper placebo minus baseline (scan 3 minus scan 2)
Nasal sinus (8, 12, 225) 12% 7.8
Rectal gyrus (3, 30, 222) 11% 6.5
(210, 19, 220) 7% 4.8
Right premotor (244, 1, 14) 7% 5.5
Right cerebellum (212, 278, 238) 9% 5.3
Vermis (1, 262, 220) 6% 4.6
(21, 260, 225) 6% 4.2
(1, 271, 238) 7% 4.0
Right ventral anterior cingulate (210, 28, 29) 5% 4.2
Left anterior insula (26, 14, 14) 5% 4.0
Left dorsal anterior cingulate (19, 5, 43) 25% 24.0
Right medial frontal (217, 210, 52) 25% 24.0
Right precuneus (212, 253, 52) 25% 24.1
Right middle temporal (239, 260, 2) 25% 24.3
Right superior frontal (221, 5, 40) 26% 24.8
Nicotine minus pepper placebo (scan 5 minus scan 3)
Left cerebellum (28, 272, 240) 9% 4.5
Thalamus (23, 210, 9) 6% 4.4
Primary visual cortex (3, 278, 11) 6% 4.4
(6, 294, 211) 5% 4.0
Right inferior frontal (248, 32, 29) 6% 4.3
(248, 23, 214) 6% 4.3
(255, 21, 0) 5% 4.1
Pons (10, 226, 222) 6% 4.1
Right superior temporal (251, 19, 216) 6% 4.1
Right middle frontal (237, 41, 214) 6% 4.1
Right inferior frontal (257, 17, 2) 5% 4.0
*In this and the following table coordinates are per Talairach and Tournoux,
1998. ( x, y, z), positive x in the left hemisphere, positive y in the anterior portion
of the brain, positive z in the superior portion of the brain.
% Change relative to global cerebral blood flow in this and the following table
with Z scores . 4 and , 24.
TABLE II. Normalized changes in regional cerebral blood flow







Recovery (nicotine) minus baseline (scan 6 minus scan 2)
Rectal gyrus (6, 30, 222) 7% 5.7
(1, 50, 218) 7% 4.1
Ventral medial
frontal (3, 37, 211) 6% 4.3
Right cerebellum (228, 260, 216) 26% 24.2
Left cerebellum (35, 255, 218) 26% 24.5
Recovery (placebo) minus baseline (scan 4 minus scan 2)
Ventral medial
frontal (3, 32, 214) 6% 4.5
Rectal gyrus (1, 35, 220) 6% 4.5
CO2 minus baseline (scan 1 minus scan 2)
Rectal gyrus (3, 30, 216) 6% 4.8
Left amygdala (24, 21, 218) 5% 4.2
Right posterior para-
hippocampal (212, 244, 24) 5% 4.0
Right precuneus (210, 260, 27) 25% 24.2
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parahippocampal gyrus demonstrated a trend of “pos-
itive” correlation (Z 5 3.4, Fig. 4). The analysis of
gender differences did not show any brain structures
where brain responses to nicotine were statistically
different between male and female subjects.
The results of 5% CO2/95% O2 inhalation demon-
strated three foci of significant relative regional in-
crease in brain activities (Fig. 2, Table II). Except for
the activation in the rectal gyrus, there was no overlap
between changes seen with nicotine spray and those
with CO2 inhalation. The mean 6 arterial pCO2 for
scan 1 was 38.3 6 4.5 mm Hg immediately after inha-
lation of 5% CO2/95% O2 and 35.8 6 3.7 mm Hg after
approximately 12–15 min breathing room air for scan
2. The mean 6 SD increment in pCO2 was 2.4 6 2.9
mm Hg.
In contrast, the mean 6 SD pO2 for scan 1 was
271.9 6 63.4 and for scan 2 89.4 6 14 mm Hg. The
mean 6 SD increment in pO2 was 182.5 6 64.8.
Therefore, the pO2 increased, whereas the pCO2 only
increased negligibly during 5% CO2/95% O2 inhala-
tion. In these tobacco-smoking volunteers who were
abstinent overnight and breathing only room air, the
mean pCO2 and pO2 levels did not change. They were
similar in the normal range for the remaining five
PET scans.
DISCUSSION
Nasal nicotine administration induces burning,
stinging, and an odor (Hummel et al., 1992). The nico-
tine molecule contains a pyridine-pyrrolidine chemical
structure; its odor is similar to that of pyridine and
pyrroles. There is evidence that nicotine also selec-
tively stimulates an olfactory nAChR (Edwards et al.,
1987). Oleoresin of pepper induces burning and sting-
ing but does not smell like nicotine and, presumably, is
not acting through an nAChR mechanism. As described
above, subjects blinded to the nasal sprays did not
consistently identify correctly the nicotine from the
pepper spray. However, even when blinded the inves-
tigators easily identified the nicotine spray on the basis
of its obvious cardiovascular effects. It is of interest
that tobacco smokers show tolerance and, when absti-
nent, have increased sensitivity to the odor of nicotine
but no difference in their olfactory thresholds to men-
thol compared to nonsmokers (Rosenblatt et al., 1998).
Although oleoresin of pepper is not a perfect placebo
control, it is an appropriate active placebo for the irri-
tant effects of nasal nicotine. The present study indi-
cates that both irritants produced similar changes in
rCBF in some brain areas such as somesthetic area II
in the neocortex, thought to be involved in motor move-
ment planning. An important data analysis issue is the
fact that the rCBF changes were normalized to global
activity. This is because the effects of nicotine on global
activity are more variable. Most activation studies now
use normalization of the data to better assess rCBF
changes, as was done in the present study.
The PET data from the mean postplacebo scan #3
was subtracted from the mean postnicotine scan #5 to
rule out the contribution of the nasal irritation pro-
duced by both agents. It was then possible to determine
the predominant effects of nicotine alone. Clearly, nic-
otine increased rCBF in the thalamus, pons, and area
17 of the visual cortex. Therefore, these data are con-
sistent with the known brain distribution of nAChR in
Fig. 4. Correlation between regional blood flow and arterial nico-
tine levels. A negative correlation indicates that rCBF decreases
relative to an increase in arterial nicotine concentration. A positive
correlation indicates that rCBF increases with an increase in arterial
nicotine concentration. The brain slice levels in stereotactic coordi-
nates are below the anterior and posterior commissural line.
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both animals and man. In particular, the relative in-
creases in CBF in the human thalamus and visual
system agree with the London et al. (1988a,b) and
London (1995) findings that nicotine increases rat tha-
lamic and visual system glucose utilization. Further-
more, Domino et al. (2000) reported that nicotine also
increases relative thalamic glucose utilization in hu-
mans.
A key experimental design feature was that the sub-
jects in the present research were relaxed and awake
with their eyes closed. They were requested to relax as
much as possible and to try not to think of anything.
Obviously, this is impossible to achieve, but is ex-
tremely important. Therefore, in this study the sub-
jects’ brains were at rest as much as possible in a PET
suite, as opposed to being involved in a behavioral task.
Thus, the results of this study are to be compared and
contrasted to those in which subjects are at rest or
involved in behavioral tasks (Flaum et al., 1997; Ernst
et al., 1997, 1998; Ghatan et al., 1998; London et al.,
1998; Nagata et al., 1998; Rose et al., 1998; Stein et al.,
1998). These latter studies did not report any striking
effects of nicotine and/or tobacco smoking on thalamic
CBF. Perhaps the behaviors studied increased tha-
lamic blood flow and obscured the drug effect.
Roland (1993) summarized a number of human PET
studies involving behavioral tasks alone that altered
thalamic rCBF or rCMRglu. In general, the thalamus
is activated when one is thinking. Tasks that require
complex cognition, scrutinizing, attention, language,
learning, recognition, vigilance, and sensory motor be-
haviors activate various thalamic nuclei. The PET
scanner used in the present study was unable to dif-
ferentiate whether specific relay or nonspecific tha-
lamic nuclei had the greatest increase in rCBF follow-
ing nicotine. The fact that the human thalamus is
activated by nicotine is consistent with behavioral
studies on the increased arousal and improvement in
performance after tobacco smoking (Wesnes and War-
burton, 1978; Sherwood, 1993, 1994; Domino et al.,
1997a,b; Pritchard and Robinson, 1998; Warburton
1998).
An especially interesting finding in the present study
is the relationship between the peak arterial nicotine
concentrations and rCBF in the area of the hippocam-
pus. It is well known that nAChRs, especially of the a7
subtype, are present and are involved in the behavior-
al/evoked potential phenomena of prepulse inhibition.
Prepulse inhibition, which is deficient in schizophrenic
patients and their relatives, is transiently normalized
by nicotine (Adler et al., 1992).
The 5% CO2/95% O2 (scan 1) was used as a vascular
control for nicotine. Inasmuch as 5% CO2 is a cerebral
vascular dilator and nicotine is a cerebral vascular
dilator as well as a vascular constrictor, the rationale
for the use of CO2 is weak, at best. Furthermore, with
95% O2, one would expect a much higher arterial pO2
than the mean increase to 271.9 mm Hg. In addition,
the slight arterial pCO2 increase to only 38.3 mm Hg
indicates that the face mask method used in this study
must have allowed considerable mixing with room air,
even though precautions were taken to prevent this.
Therefore, the very limited rCBF changes restricted to
only a few brain regions must be interpreted with this
in mind. Furthermore, why the right precuneus
showed a significant (Z score 5 24.2) decrease in CBF
is unknown.
In conclusion, the present study with nicotine in
overnight abstinent tobacco smokers supports a large
body of both animal and human data that nicotine has
very important regional CNS actions. These help to
relate its reinforcing and tobacco dependence actions to
specific brain structures.
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